問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Urology

Division of Others-

Division of Obstetrics & Gynecology

National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of Hematology & Oncology

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

蘇五洲Su, Wu-Chou
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

Recruiting Trial

222Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蘇五洲

List

439Cases

2015-06-02 - 2019-11-30

Phase II

A Phase 2, multicenter, randomized, double-blind study of ficlatuzumab plus erlotinib versus placebo plus erlotinib in subjects who have previously untreated metastatic, EGFR-mutated non-small cell lung cancer (NSCLC) and BDX004 Positive Label.

  • Condition/Disease

    NSCLC

  • Test Drug

    Ficlatuzumab (AV-299),

Participate Sites
8Sites

Terminated7Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2017-04-25 - 2019-12-31

Others

An Open-label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients with Advanced Solid Tumor Malignancies

  • Condition/Disease

    solid tumor

  • Test Drug

    Sym015

Participate Sites
6Sites

Recruiting2Sites

Terminated3Sites

邱昌芳
China Medical University Hospital-Taipei

未分科

2016-08-08 - 2019-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2018-01-01 - 2020-06-30

Phase I

A PHASE 1 STUDY OF HLX10, A HUMANIZED MONOCLONAL ANTIBODY TARGETING PROGRAMMED DEATH-1 (PD-1) PROTEIN IN PATIENTS WITH ADVANCED SOLID TUMORS

  • Condition/Disease

    solid tumor

  • Test Drug

    HLX10

Participate Sites
5Sites

Recruiting5Sites

趙祖怡
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

2018-06-15 - 2021-06-30

Phase III

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer(EV-301)

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cancer

  • Test Drug

    enfortumab vedotin

Participate Sites
6Sites

Recruiting5Sites

Study ended1Sites

林永昌
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-03-01 - 2019-09-30

Others

Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Condition/Disease

    Non-Small Cell Lung Cancer, NSCLC

  • Test Drug

    G1T38

Participate Sites
10Sites

Terminated9Sites

2020-09-15 - 2024-03-29

Phase III

A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Condition/Disease

    Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Test Drug

    Lazertinib

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2020-07-22 - 2025-11-30

Phase III

An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cancer

  • Test Drug

    Enfortumab vedotin

Participate Sites
7Sites

Recruiting7Sites

2019-09-01 - 2022-08-31

Phase I

A PHASE 1 DOSE FINDING/EXPANSION STUDY OF HLX55, A MONOCLONAL ANTIBODY TARGETING TYROSINEPROTEIN KINASE MET (C-MET) IN PATIENTS WITH ADVANCED SOLID TUMORS REFRACTORY TO STANDARD THERAPY

  • Condition/Disease

    solid tumor

  • Test Drug

    HLX55

Participate Sites
4Sites

Recruiting4Sites

2009-11-01 - 2011-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Study ended3Sites

1 35 36 37 38 39 44
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB